title: Cyclosporine C2 levels in de novo renal allograft recipients: a German multicenter prospective observational study.
abstract: This ongoing multicenter prospective observational study was undertaken in de novo renal allograft recipients managed with cyclosporine (CsA) trough (C0) and 2-hour postdose (C2) level monitoring at defined times so as to assess the risk for an acute rejection episode or allograft dysfunction. The renal transplant recipients (n = 159) were enrolled at 11 German centers. The 6-month posttransplant data from 138 patients were evaluable for this interim analysis. Mean C2 levels (ng/mL), which were measured by liquid chromatography-tandem mass spectrometry at a central laboratory, were: days 3 to 5: 873.1 +/- 391.9; days 7 to 10: 939.1 +/- 422.8; days 14 to 28: 1116.3 +/- 497.6; 3 months: 905.0 +/- 316.8; and after 6 months: 787.0 +/- 276.5. To identify patients at higher risk for acute rejection or allograft dysfunction, we calculated the relative CsA absorption capacity (C2 [ng/mL]/morning dose [mg/kg]; CsA-Abs), yielding mean values on days 3 to 5: 284.4 +/- 115.1; days 7 to 10: 306.7 +/- 134.8; days 14 to 28: 382.5 +/- 164.7; month 3: 501.5 +/- 168.8; month 6: 512.7 +/- 176.5. Three groups were distinguished by CsA-Abs at days 7 to 10: low absorbers (CsA-Abs < 200), normal absorbers (CsA-Abs 200 to 350), and high absorbers (CsA-Abs > 350). A between-group comparison of absorption level at 6 months posttransplant revealed the incidences of biopsy-proven acute rejection and Cockcroft-Gault formula-based mean glomerular filtration rates of 23.8% and 54.7 +/- 19.0 mL/min, 22.6% and 59.5 +/- 20.7 mL/min, and 17.6% and 67.7 +/- 23.5, respectively. In conclusion, mean C2 levels >1000 ng/mL are attained within 2 to 4 weeks, with CsA-Abs increasing continuously over the first 6 posttransplant months. High CsA absorbers show a propensity toward good allograft function and lower acute rejection rates at 6 months after renal transplantation.
authors.affiliation: Transplant Center, Kliniken der Stadt Koeln, Koeln, Germany. wolfgang.arns@uni-koeln.de
authors.forename: W
authors.initials: W
authors.lastname: Arns
authors.forename: F
authors.initials: F
authors.lastname: Zantvoort
authors.forename: D
authors.initials: D
authors.lastname: Abendroth
authors.forename: H
authors.initials: H
authors.lastname: Seiter
authors.forename: E-H
authors.initials: EH
authors.lastname: Scheuermann
authors.forename: U
authors.initials: U
authors.lastname: Albert
authors.forename: R
authors.initials: R
authors.lastname: Stahl
authors.forename: P
authors.initials: P
authors.lastname: Fornara
authors.forename: L
authors.initials: L
authors.lastname: Fricke
authors.forename: H H
authors.initials: HH
authors.lastname: Neumayer
authors.forename: E
authors.initials: E
authors.lastname: Nagel
authors.forename: U
authors.initials: U
authors.lastname: Michel
authors.forename: B
authors.initials: B
authors.lastname: Ulbricht
mesh_terms: D019540:Area Under Curve; D016572:Cyclosporine / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016903:Drug Monitoring / Q000379:methods; D005858:Germany; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D008657:Metabolic Clearance Rate; D011446:Prospective Studies
chemical_list: D016572:Cyclosporine